Reset filter
Keywords
Onkologie, medizinische ×
Mostra di più Keywords
Sommario
  1. 1. Test clinico
  2. 2. Documentazione di routine
  3. 3. Registro / studio di coorte
  4. 4. Garanzia di qualità
  5. 5. Dati Standard
  6. 6. Risultato segnalato dal paziente
  7. 7. Specialità mediche
    1. 7.1. Anestesiologia
    1. 7.2. Dermatologia
    1. 7.3. orecchio naso gola
    1. 7.4. Geriatria
    1. 7.5. Ginecologia / Ostetricia
    1. 7.6. Medicina Interna
      1. Ematologia
      1. Malattie infettive
      1. Cardiologia / Angiologia
      1. pneumologia
      1. Gastroenterologia
      1. Nefrologia
      1. Endocrinologia / Malattie metaboliche
      1. Reumatologia
    1. 7.7. Neurologia
    1. 7.8. Oftalmologia
    1. 7.9. Cure palliative
    1. 7.10. Patologia / Forense
    1. 7.11. Pediatria
    1. 7.12. Psichiatria / Psicosomatica
    1. 7.13. Radiologia
    1. 7.14. Chirurgia
      1. Chirurgia generale / viscerale
      1. Neurochirurgia
      1. Chirurgia plastica
      1. Chirurgia toracica
      1. Trauma / Ortopedia
      1. Chirurgia vascolare
    1. 7.15. Urologia
    1. 7.16. Medicina odontoiatrica / OMS
Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

22 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Eligibility Renal Cell Carcinoma NCT00610389

- 20/09/21 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00610389

Eligibility Renal Cell Carcinoma NCT00448721

- 28/09/18 - 1 modulo, 2 itemgroups, 15 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00448721

Eligibility Kidney Tumor NCT01967407 DRKS00004266

- 23/07/17 - 1 modulo, 2 itemgroups, 33 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: Johann J. Wendler, MD, Dr. med., University of Magdeburg ClinicalTrials.gov Identifier: NCT01967407 History of Changes Other Study ID Numbers: DE-UKMD-URO-001 DRKS00004266 ( Other Identifier: DRKS (German Clinical Trials Registry) ) U1111-1140-0415 ( Other Identifier: Universal Trial Number (UTN) ) DRKS00004266 ( Other Identifier: Internat. Clinical Trials Registry Platform ICTRP, WHO ) EUDAMED-No.: CIV-12-04-006021 ( Other Identifier: BfArM, German Federal Inst. for Drugs & Medical Devices ) 00020520 ( Other Identifier: DIMDI, German Inst. for Med. Documentation & Information ) Study First Received: October 15, 2013 Last Updated: November 18, 2014

Eligibility Renal Cell Carcinoma DRKS00007604 DRKS00006193 NCT02208128 DRKS00006193 - Eligibility Renal Cell Carcinoma NCT02208128 DRKS00006193

- 25/06/17 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: Heidelberg University ClinicalTrials.gov Identifier: NCT02208128 History of Changes Other Study ID Numbers: S-539/2013 DRKS00006193 ( Other Identifier: Deutsches Register Klinischer Studien ) Study First Received: June 2, 2014 Last Updated: July 31, 2014 Molecular Determinants for Therapy Response on Renal Cell Carcinoma (MORE) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT02208128

DC/RCC Fusion Vaccine in Renal Cell Carcinoma NCT01441765 - Eligibility

- 21/05/19 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of PD-1 Blockade Alone or In Conjunction With the Dendritic Cell (DC)/Renal Cell Carcinoma (RCC) Fusion Cell Vaccination; ODM derived from: https://clinicaltrials.gov/show/NCT01441765

HYCAMTIN in Combination With Carboplatin in Subjects with Ovarian Cancer; NCT00316173 - End of Treatment

- 12/07/19 - 1 modulo, 7 itemgroups, 40 elementi, 1 linguaggio
Itemgroups: Administrative documentation, Vital Signs, Lesion, Indicator, Evaluation, Non-Measurable Lesion, Evaluation, Response to treatment, Evaluation, Laboratory Procedures, Hematology finding, Laboratory Procedures, Chemistry, Clinical
Study ID: 104864/902 Clinical Study ID: 104864/902 Study Title: An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 Every 21 Days) HYCAMTIN in Combination With Carboplatin (Day 1 Every 21 Days) as Second-Line Therapy in Subjects With Potentially Platinum-Sensitive Relapsed Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00316173 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: CARBOPLATIN Study Indication: Ovarian Cancer; Neoplasms, Ovarian

Liver and Renal Function After Different Contrast Media NCT01563484 - Eligibility Criteria

- 20/09/21 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media; ODM derived from: https://clinicaltrials.gov/show/NCT01563484

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - CRF Tracking/Review Forms

- 22/08/19 - 1 modulo, 2 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Administrative documentation, Clinical Trial Regulatory Tracking Document
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Topotecan Post-Study Minimal Follow-up Report

- 21/08/19 - 1 modulo, 5 itemgroups, 19 elementi, 1 linguaggio
Itemgroups: Administrative documentation, Follow-Up Report, Month, Patient Outcome, Cessation of life, Investigator Signature
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Patient Assignment Sheet

- 21/08/19 - 1 modulo, 2 itemgroups, 9 elementi, 1 linguaggio
Itemgroups: Administrative documentation, Patients, Assignment
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Patient Log

- 21/08/19 - 1 modulo, 2 itemgroups, 5 elementi, 1 linguaggio
Itemgroups: Administrative documentation, Patients, Exclusion
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Laboratory Reference Ranges

- 21/08/19 - 1 modulo, 2 itemgroups, 6 elementi, 1 linguaggio
Itemgroups: Administrative documentation, Reference lab test reference range
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial